ストックスクリーナーアプリを入手
3.36
7.20%
-0.25
前日終値:
$3.61
開ける：
$3.45
24時間の取引高:
636.17K
Relative Volume:
0.06
時価総額：
$10.90M
収益：
$960.60K
当期純損益:
$-7.10M
株価収益率:
-0.4444
EPS:
-7.56
ネットキャッシュフロー:
$-8.00M
1週間 パフォーマンス:
+13.95%
1か月 パフォーマンス:
+141.01%
6か月 パフォーマンス:
+37.86%
1年 パフォーマンス:
-24.89%
1日の値動き範囲:
$3.3184
$3.72
1週間の範囲:
$2.68
$6.2299
52週間の値動き範囲:
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
SNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
3.34 | 16.19M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.76 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.24 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.75 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.51 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
314.35 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-28 | ダウングレード | Dawson James | Buy → Neutral |
| 2018-01-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 繰り返されました | Maxim Group | Buy |
| 2017-07-17 | 開始されました | H.C. Wainwright | Buy |
Soligenix Inc (SNGX) 最新ニュース
Are Bears Losing Grip on Soligenix Inc.2025 Top Gainers & Fast Entry Momentum Trade Alerts - newsyoung.net
NovaBay Names New CEO, Rocket Soars As FDA Lifts Clinical Hold, Celldex Plunges, Soligenix On Watch - RTTNews
Companies Like Soligenix (NASDAQ:SNGX) Could Be Quite Risky - Yahoo Finance
SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease - Yahoo Finance
Soligenix shares rise 9.46% premarket after receiving Nasdaq notice for non-compliance with equity requirement. - AInvest
Top Penny Stocks to Watch Now: Soligenix, Catheter Precision, and Wellgistics Health - AInvest
Promising Defense Stocks To Add to Your WatchlistAugust 18th - MarketBeat
Soligenix Plunges 27%—What's Behind the Sudden Sell-Off Amid Orphan Drug Designation? - AInvest
Soligenix (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease - The Globe and Mail
Why SNGX Gains 8% Amid Positive Trends? - StocksToTrade
Soligenix Plunges 17.74% After FDA Orphan Drug Designation - AInvest
Soligenix shares fall 18.55% premarket after receiving Nasdaq notice for non-compliance with equity requirement. - AInvest
Soligenix's 78.42% Surge on FDA Orphan Drug Designation Drives $890M Trading Volume Ranks 87th in Market Activity - AInvest
Penny Stocks on the Move: Today’s Top Gainers and Biggest Decliners - AInvest
FDA Grants Orphan Drug Designation to Soligenix's Dusquetide for Behçet’s Disease Treatment - citybuzz -
Soligenix Skyrockets 87%—Is This the Start of a Biotech Revolution? - AInvest
Top Midday Gainers - MarketScreener
Why Is Soligenix Stock Soaring On Monday? - Benzinga
Soligenix (SNGX.O) Makes Wild Intraday Move—What’s Driving It? - AInvest
Soligenix Shares Surge After FDA Grants Orphan Drug Status - MSN
Regression Model Predicts Rangebound Movement in Soligenix Inc.2025 Big Picture & Daily Technical Forecast Reports - beatles.ru
Soligenix stock soars after FDA grants orphan drug designation By Investing.com - Investing.com Canada
Soligenix (SNGX) up more than 300% since Jul 29 - AInvest
Soligenix stock soars after FDA grants orphan drug designation - Investing.com
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results - The Malaysian Reserve
Soligenix (SNGX) Stock Surges on FDA Orphan Drug Designation for Rare Disease Treatment – A Big Win for This Biotech Underdog - RagingBull
Soligenix Inc.: An Unexpected Surge? - StocksToTrade
Soligenix Soars 90% on FDA Orphan Drug Designation – What’s Next for SNGX? - AInvest
Soligenix Gains FDA Orphan Drug Designation for Dusquetide - TipRanks
FDA grants soligenix orphan drug designation for behçet’s disease - Investing.com
Why Soligenix Is Rising In Pre-market? - Nasdaq
2025-08-18 | FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results | NDAQ:SNGX | Press Release - Stockhouse
Drawdown in Soligenix Inc. May Be Nearing EndStock Surge & AI Forecasted Entry and Exit Points - beatles.ru
Soligenix Faces Nasdaq Non-Compliance Notice - MSN
New Study Challenges Traditional Psoriasis Severity Classification - citybuzz -
Soligenix's Nasdaq Non-Compliance: A High-Stakes Balancing Act for Long-Term Investors - AInvest
Soligenix Receives Nasdaq Notice for Non-Compliance with Equity Requirement - AInvest
Soligenix Advances Heat-Stable Ricin Vaccine Amid Global Biothreat Concerns - citybuzz -
Soligenix receives Nasdaq notice for non-compliance with equity listing rule - Investing.com
Soligenix shares fall 5.78% premarket after announcing recent accomplishments and financial results. - AInvest
What makes Soligenix Inc. stock price move sharplyEarnings Beat & Smart Investment Allocation Insights - 선데이타임즈
Soligenix's Surprising Earnings Beat Amid Deepening Losses and High Volatility: A Biotech Inflection Point? - AInvest
Soligenix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Soligenix Reports Q2 2025 Results, Confident in Late-Stage Rare Disease Pipeline - AInvest
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results - Barchart.com
Soligenix’s Phase 3 Study on HyBryte for CTCL: Key Insights for Investors - MSN
Soligenix Inc. Stock Recovery Path — Analyst BreakdownJuly 2025 Rallies & Consistent Income Trade Recommendations - 선데이타임즈
Is Soligenix Inc. a stock for growth or value investorsFast Explosive Return Stocks - newsyoung.net
Alliance Global Partners Raises Soligenix Price Target Amid Clinical Advancements - citybuzz -
Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix (NASDAQ: SNGX) Advances Proprietary Clinical Programs - Barchart.com
How do insiders feel about Soligenix Inc.Free Investment Newsletter - classian.co.kr
Soligenix Inc (SNGX) 財務データ
収益
当期純利益
現金流量
EPS
1.33%
0.64%
大文字化:
|
ボリューム (24 時間):